All Penny Stocks.com News: Lipocine's Shares Surge as Company's Oral Testosterone Replacement Therapy Successful in Mid-Stage Study

Mississauga, ON -- (SBWIRE) -- 09/26/2016 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Lipocine's Shares Surge as Company's Oral Testosterone Replacement Therapy Successful in Mid-Stage Study."

Companies mentioned in this article include iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and Lipocine Inc. (NASDAQ:LPCN).

Article Excerpt:

The biotech sector has seen a pullback in trading today, tracking losses in the broader market. However, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) did break through a key resistance level on Friday.

The IBB had seen a sharp sell-off at the start of this year, dropping well below $300. Although the sector did rebound, it failed to break through $300 until last week. The sector has been driven higher by a spate of positive news relating to the sector. In the past few months, we have seen several acquisitions announced, which should provide support to the sector. We also seen some positive sentiment due to recent drug approvals.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/674/lipocines-shares-surge-as-companys-oral-testosterone-replacement-therapy-successful-in-mid-stage-study.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:

AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.

For more information on this press release visit: http://www.sbwire.com/press-releases/all-penny-stockscom-news-lipocines-shares-surge-as-companys-oral-testosterone-replacement-therapy-successful-in-mid-stage-study-726821.htm

Media Relations Contact

Peter Szafranski
Telephone: 905-361-5680
Email: Click to Email Peter Szafranski
Web: http://www.allpennystocks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X